Ziccum AB is a Sweden-based pharmaceutical company that is mainly engaged in developing vaccines. Ziccum develops new thermostable versions of vaccines and biologics for licensing to vaccine suppliers, developers, manufacturers and CDMOs in the global pharmaceutical industry. Ziccum's patented drying technology, LaminarPace, is unique. It can dry-formulate temperature-sensitive vaccine materials at room temperature with high yield and low waste. These robust, thermostable dry powders can be stored and transported worldwide without the need for a cold chain or freezing. The company conducts its business by entering into strategic collaborations with major pharmaceutical companies and offering licenses to the Company's patented technology.
Metrics to compare | ZICC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipZICCPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.0x | −5.4x | −0.6x | |
PEG Ratio | −0.25 | −0.13 | 0.00 | |
Price/Book | 5.6x | 5.8x | 2.6x | |
Price / LTM Sales | 6.1x | 16.2x | 3.2x | |
Upside (Analyst Target) | - | 72.9% | 46.5% | |
Fair Value Upside | Unlock | 0.7% | 6.6% | Unlock |